Emily Weimin Cheng

US Patent:

59075708, May 25, 1999

Filed:

Oct 22, 1997

Appl. No.:

8/955768

Inventors:

William L. Nighan - Menlo Park CA
Mark S. Keirstead - San Jose CA
Emily Cheng - Sunnyvale CA

Assignee:

Spectra-Physics, Inc. - Mountain View CA

International Classification:

H01S 316

US Classification:

372 41

Abstract:

A diode pumped laser includes a resonator mirror and an output coupler, defining a laser resonator with a resonator optical axis. A strong thermal lens gain medium with a TEM. sub. 00 mode diameter is mounted in the resonator along the resonator optical axis. The dopant level of the gain medium is in the range of 0. 01 to less than 0. 5 percent. A diode pump source supplies a pump beam to the gain medium in the laser resonator, and produces an output beam with a diameter larger than the TEM. sub. 00 mode diameter to reduce thermal birefringence. A power source supplies power to the diode pump source. A polarizing element can be positioned in the resonator, along with a aperture stop The laser operates well over a large range of pump powers. Its slope efficiency in the TEM. sub. 00 mode is greater than 40%, with an overall efficiency greater than 25%.

US Patent:

62872982, Sep 11, 2001

Filed:

Apr 30, 1998

Appl. No.:

9/070478

Inventors:

William L. Nighan - Menlo Park CA
John Cole - Sunnyvale CA
Emily Cheng - Sunnyvale CA

Assignee:

Spectra-Physics Lasers, Inc. - Mountain View CA

International Classification:

A61F 9008

US Classification:

606 10

Abstract:

A diode pumped, multi axial mode, intracavity doubled laser has at least two resonator mirrors that define a resonator cavity. A Nd:YVO. sub. 4 laser crystal and a LBO doubling crystal are positioned in the resonator cavity. A diode pump source supplies a pump beam to the laser crystal and produces a laser crystal beam with at least three axial modes that are incident on the doubling crystal. A frequency doubled output beam is generated with an output power of at least 1 watt.

US Patent:

20160067229, Mar 10, 2016

Filed:

Sep 14, 2015

Appl. No.:

14/853468

Inventors:

- New York NY, US
Michael Berger - New York NY, US
Robert Motzer - Ridgewood NJ, US
Martin H. Voss - New York NY, US
Ari A. Hakimi - New Rochelle NY, US
Can Pham - New York NY, US
Emily Cheng - Englewood Cliffs NJ, US
Rose Brannon - Cambridge MA, US
Jianing Xu - Bronx NY, US

International Classification:

A61K 31/436
C12Q 1/68

Abstract:

The present invention relates to the use of one or more biomarkers to evaluate the likelihood that a rapamycin analog would produce an anti-cancer effect in a subject. It is based, at least in part, on the results of experiments employing an integrated next-generation sequencing approach to interrogate spatially separated tumor specimens from the same individuals to decipher intra-tumor and intertumor heterogeneity and determine the oncogenomic basis of exceptional therapeutic benefit to rapalogs in kidney cancer patients. These experiments implicated loss of function mutations in TSC1 and/or TSC2 and/or gain-of-function of mTOR in therapeutic responsiveness to rapamycin analogs. Accordingly, in non-limiting embodiments, the present invention provides for assay methods and kits for determining the presence of loss of function mutations in TSC1 and/or TSC2 and/or gain-of-function of mTOR, and methods of using such determinations in selecting a therapeutic regimen for a cancer patient and in methods of treating cancer patients. In particular non-limiting embodiments, a plurality of tumor sites are evaluated and the composite effect of the genetic background on mTOR function is assessed.